Laurus Labs Ltd

LAURUSLABS

Company Profile

  • Business description

    Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.

  • Contact

    Road No. 7, Banjara Hills
    2nd Floor, Serene Chambers
    HyderabadTG500034
    IND

    T: +91 4039804333

    https://www.lauruslabs.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 March 2026

    Employees

    12,467

Stocks News & Analysis

stocks

Overvalued ASX share as market underestimates downside risks

Growth outlook solid, but upside more than priced in.
stocks

New production imminent for undervalued ASX gas play

LNG project receives first commissioning gas.
stocks

Going into earnings, is Tesla stock a buy, a sell, or fairly valued?

Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,324.6040.800.44%
CAC 408,206.0717.480.21%
DAX 4024,291.19460.201.93%
Dow JONES (US)46,554.00363.390.79%
FTSE 1009,403.5749.000.52%
HKSE25,858.83611.732.42%
NASDAQ22,993.33313.351.38%
Nikkei 22549,185.501,603.353.37%
NZX 50 Index13,344.9655.750.42%
S&P 5006,729.9765.960.99%
S&P/ASX 2009,031.9043.700.49%
SSE Composite Index3,863.8924.140.63%

Market Movers